Your search history is turned on.
Date: May 1, 2024 17:44:09 EST Jurisdictions: All jurisdictions
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's commercialization rights to Metoj...
Date: April 2, 2024 Jurisdictions: All jurisdictions
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024. Event: 2024 Bloom Burton & Co...
Date: March 26, 2024 Jurisdictions: All jurisdictions
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: M...
Date: February 7, 2024 Jurisdictions: All jurisdictions
1 Form 52-109F2 Certification of Interim Filings Full Certificate I, Marcel Konrad, Chief Financial Officer of Medexus Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Medexus Pharmaceuticals Inc. (the issuer) for the i...
1 Form 52-109F2 Certification of Interim Filings Full Certificate I, Ken dEntremont, Chief Executive Officer of Medexus Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Medexus Pharmaceuticals Inc. (the issuer) for the interim period ended December 31,...
Managements Discussion & Analys is For the three- and nine-month per iods ended December 31, 2023 i Table of Contents Preliminary Notes ..................................................................................................................... ii Company Overview .........
Medexus Pharmaceuticals Inc. Condensed Interim Consolidated Financial Statements (unaudited) For the three- and nine-month periods ended December 31, 2023 (expressed in thousands of United States dollars) Medexus Pharmaceuticals Inc. Interim Consolidated Statements of Financial Position (una...
Medexus Announces Fiscal Q3 2024 Results Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its o...
Date: January 30, 2024 Jurisdictions: All jurisdictions
Medexus Schedules Third Fiscal Quarter 2024 Conference Call Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 8, 2024 to discuss Medexus's results for its third fiscal quarter ended December 31, 2023. Medexus expects to file its financial state...
Date: January 8, 2024 Jurisdictions: All jurisdictions
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine Topical terbinafine has been widely used in other markets to treat fungal nail infections If and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million on an annual basis* Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 8, 2024) - Medex...